Regulation of a   -adrenoceptor gene expression by chronic XXXX treatment in @entity35 brain.

@entity162 @entity13557 @entity21241 @entity11026 @entity35 @entity1091
One of the approaches for the treatment of @entity162 involves the coadministration of @entity1091 , a mood stabilizer, with a   -adrenoceptor antagonists possessing an antidepressant effect. Since @entity1091 accelerates the recovery of a   (D)-adrenoceptors following their irreversible inactivation with @entity21241 ( @entity21241 ), our aim was to examine if it could be to some changes in @entity11026 gene expression which codifies these adrenoceptors. Animals were treated with @entity13557 (120 mg/kg i.p.) or saline once a day for 10 days. A group of @entity1091 - or saline-treated @entity35 was killed 48 h after the last injection. The remaining animals were treated with EEDQ and were killed at 0.25, 4 and 14 days following this administration. Total RNA was extracted from cerebral cortex and @entity11026 gene expression was measured by RT-QPCR. The results show that chronic @entity1091 raised the @entity11026 gene expression (P < 0.05), and after EEDQ administration this expression decreased to the basal level. No change in @entity11026 gene expression was detected in the saline-treated group. However, EEDQ administration produced an insignificant increase in a   -adrenoceptors mRNA levels followed by a progressive decrease until basal levels. @entity1091 produced an overexpression of the @entity11026 gene after chronic treatment that made the neuron ready to produce a   -adrenoceptors to deal with their inactivation.
